Kestra Medical Technologies (NASDAQ:KMTS) Now Covered by Analysts at Wells Fargo & Company

Research analysts at Wells Fargo & Company began coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS) in a report released on Monday, Marketbeat.com reports. The brokerage set an “overweight” rating and a $28.00 price target on the stock. Wells Fargo & Company‘s price objective points to a potential upside of 20.38% from the stock’s previous close.

KMTS has been the subject of a number of other research reports. Piper Sandler assumed coverage on Kestra Medical Technologies in a research note on Monday. They issued an “overweight” rating and a $27.00 price objective for the company. The Goldman Sachs Group started coverage on Kestra Medical Technologies in a report on Monday. They set a “neutral” rating and a $24.00 price objective on the stock. Finally, Stifel Nicolaus started coverage on shares of Kestra Medical Technologies in a research report on Monday. They issued a “buy” rating and a $28.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $27.67.

Kestra Medical Technologies Stock Performance

Shares of KMTS traded down $2.44 during mid-day trading on Monday, reaching $23.26. 109,177 shares of the company were exchanged, compared to its average volume of 280,498. Kestra Medical Technologies has a 52 week low of $20.00 and a 52 week high of $26.06.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.